Ajay Major, MD, MBA
@majorajay.bsky.social did:plc:plgt5bqnko7dwhzi2436ipuf
Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
En Bluesky desde el
- Seguidores
- 588
- Siguiendo
- 252
- Posts
- 539
- Días en rankings
- 0
Resumen
Ajay Major, MD, MBA (@majorajay.bsky.social) es un usuario de Bluesky que se unió el 11 noviembre 2024. Tiene 588 seguidores, sigue a 252 cuentas y ha publicado 539 posts.
Apariciones en rankings
Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.
Esta cuenta aún no ha aparecido en un ranking diario.
Posts que le gustaron recientemente
Me gusta públicos de la red Bluesky.
Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social. Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵 doi.org/10.1016/j.bn...
Ver postSelf-promotion. news.cuanschutz.edu/cancer-cente...
Ver postJamie Studts, PhD, leads with earnestness, collaboration, and deep respect for community voice — encouraging researchers to pursue what they’re passionate about while grounding science in real-world impact. Full interview: youtu.be/RihtmBmGlIk
Ver postCAR T-cell therapy has revolutionized treatment of stubborn cancers. Now, a groundbreaking study from @cucancercenter.bsky.social researchers addresses “a huge unanswered gap” in how CAR T-cell therapy impacts patients over two years. @cuanschutz.bsky.social @majorajay.bsky.social #cucityofhealth
Ver postIn a new study, Ajay Major (@majorajay.bsky.social), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: https://bit.ly/3UzIYxF
Ver post
Cuentas que bloquea
En Bluesky los bloqueos son registros públicos.